These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11437417)

  • 1. Evaluating new treatments for advanced cancer.
    Botwood N
    Br J Cancer; 2001 Jul; 85(1):139-40. PubMed ID: 11437417
    [No Abstract]   [Full Text] [Related]  

  • 2. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New wave of chemotherapeutic agents: update in pulmonary oncology].
    Sculier JP
    Rev Mal Respir; 1997 Apr; 14(2):154-6. PubMed ID: 9198842
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
    Clegg A; Scott DA; Hewitson P; Sidhu M; Waugh N
    Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drug for therapy of non-small cell lung cancer.
    Klastersky J
    Lung Cancer; 1994 Nov; 11 Suppl 3():S139-49. PubMed ID: 7704506
    [No Abstract]   [Full Text] [Related]  

  • 6. [New drugs in gastrointestinal oncology. Current status and future directions].
    Conroy T; Paillot B; Adenis A
    Gastroenterol Clin Biol; 1999 Nov; 23(11):1145-65. PubMed ID: 10651534
    [No Abstract]   [Full Text] [Related]  

  • 7. Promising new agents in the treatment of non-small cell lung cancer.
    Edelman MJ; Gandara DR
    Cancer Chemother Pharmacol; 1996; 37(5):385-93. PubMed ID: 8599859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiosensitization with chemotherapeutic agents.
    Caffo O
    Lung Cancer; 2001 Dec; 34 Suppl 4():S81-90. PubMed ID: 11742709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemotherapy for elderly patients with lung cancer].
    Okamoto H; Watanabe K
    Nihon Rinsho; 2002 May; 60 Suppl 5():591-5. PubMed ID: 12101743
    [No Abstract]   [Full Text] [Related]  

  • 10. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine.
    Launois R; Reboul-Marty J; Henry B; Bonneterre J
    Pharmacoeconomics; 1996 Nov; 10(5):504-21. PubMed ID: 10169397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for non-platinum chemotherapy in advanced NSCLC.
    Murren JR
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):29-34. PubMed ID: 11497229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment.
    Meert AP; Berghmans T; Branle F; Lemaître F; Mascaux C; Rubesova E; Vermylen P; Paesmans M; Sculier JP
    Anticancer Res; 1999; 19(5C):4379-90. PubMed ID: 10650780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New agents in the management of advanced non-small cell lung cancer.
    Carney DN
    Semin Oncol; 1998 Aug; 25(4 Suppl 9):83-8. PubMed ID: 9728591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions.
    Khuri FR; Shin DM; Glisson BS; Lippman SM; Hong WK
    Semin Oncol; 2000 Aug; 27(4 Suppl 8):25-33. PubMed ID: 10952435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
    Ferrigno D; Buccheri G
    Lung Cancer; 2000 Aug; 29(2):91-104. PubMed ID: 10963840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in cancer therapy.
    Mercado I; Baez L; Caceres W
    Bol Asoc Med P R; 1997; 89(7-9):120-6. PubMed ID: 9419930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
    Verma S; Ilersich AL
    Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New chemotherapeutic agents for non-small cell lung cancer.
    Miller VA; Rigas JR; Grant SC; Pisters KM; Kris MG
    Chest; 1995 Jun; 107(6 Suppl):306S-311S. PubMed ID: 7781411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New cytotoxic agents and schedules for advanced breast cancer.
    Burstein HJ; Bunnell CA; Winer EP
    Semin Oncol; 2001 Aug; 28(4):344-58. PubMed ID: 11498829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
    Bunn PA; Kelly K
    Clin Cancer Res; 1998 May; 4(5):1087-100. PubMed ID: 9607565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.